News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
For Immediate Release Chicago, IL – August 11, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Illumina stock (ILMN) has rallied 40% since January, reaching a 52-week high of $204 before settling at $188, driven by strong Q2 results and raised guidance, particularly in its clinical sequencing business. Wall Street analysts are now playing catch-up, revising their price targets upward, …
Illumina, Inc. (ILMN) recently settled litigation with Icahn Partners, with the mutual release effective August 21, 2025. Additionally, Illumina expanded its Next-Generation Sequencing (NGS) access in Italy by implementing a multi-year reagent-rental agreement for a MiSeq i100 with Devyser, which shifts capital expenditure to …
Assenagon Asset Management S.A. significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 188.6% in the second quarter, now holding 140,003 shares valued at approximately $24.6 million. This comes as Illumina exceeded quarterly earnings and revenue expectations and maintained its fiscal 2026 EPS guidance. …
This article lists various ETFs that hold Illumina, Inc. (ILU) stocks, providing detailed financial information for each fund. The data includes market value, weight of ILU in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, …
Independent Director Keith Meister recently sold US$148m worth of Illumina (NASDAQ:ILMN) stock at US$200 per share, reducing his holding by 26%. While this is the largest insider sale in the last year, it occurred at approximately the current share price, mitigating some of the …
Empowered Funds LLC significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 104.2% in the first quarter, now holding 12,996 shares valued at approximately $1.6 million. This comes as institutional investors collectively own 89.42% of the company, and Illumina reported strong Q1 earnings, beating …
Illumina, Inc. (ILMN) granted its Chief Commercial Officer, Michael C. Sullivan, equity awards on August 5, 2026. These awards include restricted stock units and performance stock units, linking a portion of his compensation directly to the company's financial performance, specifically non-GAAP EPS growth and …
Sharemaestro market context Trend signal active 52 weeks +87.5%This page provides financial information for Illumina, Inc. (DUS:ILU) on the TradingView platform, specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades recorded for the company.
Illumina (ILMN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Illumina director Keith A. Meister reported that private investment funds advised by Corvex Management LP sold 741,127 shares of Illumina common stock between August 4-5, 2026. The sales occurred in multiple transactions at weighted-average prices ranging from $196.74 to $203.28 per share. This transaction …
Illumina Inc. (ILMN) stock dropped 3.08% on Thursday, closing at $193.72, underperforming the broader market. This marks the second consecutive day of losses for the stock, as the S&P 500 Index and Dow Jones Industrial Average also saw declines.
The diagnostics-and-research stock is drawing heavier activity as trend pressure improves, though Relative Strength remains below leadership territory.
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its "Mid Cap Strategy". A copy of the Q2 2026 investor letter can be downloaded here. In the quarter, equity markets posted strong returns as resilient economic growth …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%The diagnostics-and-research stock closed the week higher, with trading activity above its recent average and Market Dynamics showing confirmation.
Illumina's Chief Legal Officer, Scott M. Davies, sold 615 shares of common stock on July 30, 2026, at a price of $200.00 per share. This transaction, executed under a Rule 10b5-1 trading plan, leaves him with 20,338 shares directly owned. The sale, valued at …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Illumina reported strong Q2 2026 earnings, exceeding revenue and EPS estimates, driven primarily by robust clinical market growth. The company raised its full-year guidance for revenue and EPS, emphasizing the sustained demand for clinical sequencing, particularly with the NovaSeq X platform. TIKR's valuation model …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Shares of Illumina (ILMN) have been strong performers lately, with the stock up 8.7% over the past month. The stock hit a new 52-week high of $205.93 in the previous session. Illumina has gained 56.4% since the start of the year compared to the …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Piper Sandler has increased its target price for Illumina Inc. (ILMN.O) to $225, up from the previous target of $200. This adjustment reflects the analyst's updated outlook on the company. The article notes that the content reflects the author's opinion and is not investment …
In late July 2026, Illumina reported second-quarter results showing revenue of US$1,159 million versus US$1,059 million a year earlier, while net income eased to US$207 million from US$235 million and diluted earnings per share from continuing operations slipped to US$1.35 from US$1.49. At the …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Illumina stock has more than doubled over the past year, yet valuation checks are split, with a Discounted Cash Flow (DCF) estimate pointing to …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Illumina (ILMN) is back in focus after its Q2 2026 results beat expectations on both revenue and earnings, prompting the company to lift full year …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%In late July 2026, Illumina reported second-quarter results showing revenue of US$1,159 million versus US$1,059 million a year earlier, while net income eased to US$207 million from US$235 million and diluted earnings per share from continuing operations slipped to US$1.35 from US$1.49. At the …
Key Points Interested in Illumina, Inc.? Here are five stocks we like better. Illumina exceeded expectations in Q2: Revenue rose 9.5% year over year to $1.16 billion, while non-GAAP EPS increased 10% to $1.31. The company raised its 2026 revenue outlook to $4.60 billion–$4.64 …
ILMN Q2 Deep Dive: Clinical Strength, Platform Expansion, and Strategic Focus Drive Guidance Lift Genomics company Illumina (NASDAQ:ILMN) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company's full-year revenue guidance of $4.62 billion …
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Illumina CEO Jacob Thaysen discusses the company's earnings, genomic medicine opportunities and the potential for artificial intelligence in life sciences on "Bloomberg The Close." View Comments
Sharemaestro market context Trend signal active 52 weeks +80.0% · Next-week setup negative 18.3%Illumina, Inc.'s average 12-month price target has been increased to $193.61 from $175.72 by 18 analysts, with forecasts ranging from $95 to $230 per share. This new target suggests a 6% potential downside based on the July 30 closing price. The consensus rating for …
BofA Global Research has increased its price objective for Illumina Inc. (ILMN.O) shares. The new target price is set at $140, up from the previous $120. This adjustment indicates a more positive outlook from the research firm regarding Illumina's future stock performance.
Search by ticker symbol or company name and select a result to open its chart.